SIGNAFUSE Bioactive Bone Graft in Strip Format Receives FDA Clearance

The SIGNAFUSE Bioactive Bone Graft has been available as a putty since 2014 and coming in Q3 the Surgical Team will offer SIGNAFUSE in a new strip format. The strip format received clearance from the FDA on June 18. The new strips hydrate rapidly and provide exceptional handling properties for intraoperative flexibility.  They come in multiple sizes ranging from 25 to 200 millimeters in length, with the longer strips providing a great option for large, multilevel procedures for spine surgeons.

“The SIGNAFUSE Bioactive Bone Graft strip was developed by a cross-functional team and represents the first product done completely in-house by the Surgical Products division,” said Lawrence Boyd PhD, Vice President, Product Development. “Key contributors to this significant accomplishment include Laura McCrum and Ryan Koch (Product Development), Mark Schaefer (Manufacturing Engineering), Tejal Bhagwat (Quality Engineering), Drew Zabor (Marketing) and Natalie Biscarret (Operations). Additional novel products are under development and we look forward to many more product launches in the coming years.”

“We are excited to expand our portfolio of bone graft solutions with the SIGNAFUSE Bioactive Bone Graft strip. Apart from the ideal combination of biomaterials that contribute to healing, and best-in-class handling, this product is unique in that it offers a great solution for patients that require more significant interventions such as spinal deformity correction,” said Megan Osorio, Vice President, Marketing.

“We also believe SIGNAFUSE in the strip format will provide efficiencies for the hospital, either by opening fewer packages or cost savings opportunities vs. alternative grafts,” added John Nosenzo, Chief Commercial Officer.

In addition to all of that, the FDA clearance and impending Q3 launch of the SIGNAFUSE strips satisfies another objective on the 2020 Company Scorecard. Well done, Surgical Team.